Compare Helius Medical Technologies, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 90 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.81
138.72%
-0.59
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2025)
Net Profit:
326 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.37%
0%
1.37%
6 Months
-59.64%
0%
-59.64%
1 Year
-98.97%
0%
-98.97%
2 Years
-99.83%
0%
-99.83%
3 Years
1278.03%
0%
1278.03%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
Helius Medical Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.71%
EBIT Growth (5y)
1.57%
EBIT to Interest (avg)
-16.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
34.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.59
EV to EBIT
2.19
EV to EBITDA
2.19
EV to Capital Employed
0.12
EV to Sales
-33.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.55%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 3 Schemes (1.67%)
Foreign Institutions
Held by 21 Foreign Institutions (14.67%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
5.20
0.70
642.86%
Operating Profit (PBDIT) excl Other Income
-8.90
-4.90
-81.63%
Interest
0.00
194.70
-100.00%
Exceptional Items
346.00
-153.00
326.14%
Consolidate Net Profit
325.60
-352.80
192.29%
Operating Profit Margin (Excl OI)
-1,697.80%
-7,044.50%
534.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 642.86% vs 0.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 192.29% vs -3,500.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6.00
0.50
1,100.00%
Operating Profit (PBDIT) excl Other Income
-21.10
-13.80
-52.90%
Interest
195.80
0.00
Exceptional Items
187.10
2.90
6,351.72%
Consolidate Net Profit
-40.90
-11.70
-249.57%
Operating Profit Margin (Excl OI)
-3,510.20%
-26,659.60%
2,314.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1,100.00% vs -16.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -249.57% vs -31.46% in Dec 2024
About Helius Medical Technologies, Inc. 
Helius Medical Technologies, Inc.
Pharmaceuticals & Biotechnology
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company’s offered product is portable neuromodulation stimulator (PoNS) device. PoNS is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation.
Company Coordinates 
Company Details
642 Newtown Yardley Road , NEWTOWN PA : 18940
Registrar Details






